Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Anna Arbo has a total of 34 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Off-label prescribing in Italian pediatric practice: insights from a nationwide survey

    by Anna Arbo, Anna Flamigni, Giulia Zamagni, Sara Abbate, Giovanni Migliore, Francesca Rocchi

    Off-label prescribing in pediatric care is common due to the lack of age-specific drug formulations, posing risks to safety and efficacy. Understanding how Italian hospitals manage and regulate this practice is essential to improving oversight and promoting safer prescribing. A multicenter, cross-sectional survey was conducted from November 13, 2024, to January 31, 2025, under the Italian Network for Pediatric Clinical Trials (INCiPiT). Fifty facilities participated; 64% of those with < 5000 pediatric admissions had Neonatal Intensive Care Units (NICUs) and birth centers. Off-label prescribing was strongly associated with NICUs, increasing up to 50% following compassionate use refusal. Notably, 25% of centers were unaware of prescribing frequency. Facilities with digital tracking and dedicated research units had better regulatory compliance and higher compassionate use approval rates. Conclusion: The present analysis revealed that off-label prescribing is pervasive and predominantly driven by institutional specialization rather than hospital size. The implementation of structured oversight, digital infrastructure, and cost monitoring has been demonstrated to enhance regulatory compliance. The findings of this study support the need for standardized procedures and policy alignment to ensure safe pediatric pharmacotherapy. What is known: • Off-label drug prescribing in pediatric care is a prevalent practice, primarily attributable to the paucity of age-appropriate formulations and clinical trial data for children.This practice entails potential risks associated with drug safety, efficacy, and dosing accuracy, particularly in vulnerable populations such as neonates and infants. • Regulatory oversight and institutional awareness of off-label use vary significantly across healthcare systems, with limited data available on how hospitals manage these prescriptions at the organizational level. What is New: • This nationwide Italian survey reveals that off-label prescribing in Italian pediatric hospitals is primarily driven by institutional specialization—especially NICU presence—rather than hospital size, with digital tracking and research units linked to better regulatory compliance. • A significant portion of facilities lack awareness of their off-label prescribing rates, highlighting the need for standardized oversight and national policy alignment to ensure safer pediatric drug use.


  • Open Access

    Decentralized Clinical Trials in Pediatrics: Is Italy Ready?

    by Gilda Paternuosto, Anna Flamigni, Monica Zanier, Barbara Bonifacio, Giulia Schillani, Mario Cirino, Sasa Krcalic, Silvia Tommasi, Fatima Tizi, Anna Arbo, et al.

    Driven by technological advances and regulatory developments, the clinical trials industry is undergoing a period of transformation. Decentralized clinical trials (DCTs) promise to streamline processes, increase participant engagement and improve data quality. The pediatric clinical trial landscape is challenging, as participation in a clinical trial affects the whole family. DCTs allow for increased patient engagement, thereby improving trial quality and consequently drug safety. The Italian Medicines Agency (AIFA), in its quest for regulatory simplification and alignment with the European framework, has established comprehensive guidelines to facilitate these decentralized trials. The present work aims to delve into the regulations to understand the feasibility of conducting decentralized pediatric trials in Italy.

  • Open Access

    Improving Drug Safety in Pediatric and Young Adult Patients with Hemato-Oncological Diseases: A Prospective Study of Active Pharmacovigilance

    by Anna Parzianello, Giulia Fornasier, Valentina Kiren, Federico Pigato, Sabrina Orzetti, Giulia Zamagni, Anna Arbo, Paolo Baldo, Paola Rossi, Marco Rabusin, et al.

    The acquisition of relevant pediatric clinical safety data is essential to ensure tolerable drug therapies. Comparing the real number of Adverse Drug Reaction (ADR) reports in clinical practice with the literature, the idea of ADR underreporting emerges. An active pharmacovigilance observational prospective study was conducted to assess the safety of oncology pharmacological prescriptions in patients aged 0–24 years at Institute for Maternal and Child Health IRCCS Burlo Garofolo in Trieste and IRCCS CRO National Cancer Institute in Aviano (Italy) between January 2021 and October 2023. Prescriptions and ADRs were evaluated by a multidisciplinary team. A total of 1218 prescriptions for 38 patients were analyzed, and 190 ADRs of grade 3–5 were collected. As compared to historical data, we registered a significant increase (p < 0.001) in the number of ADRs. The risk of ADR was 3.4 times higher in the case of off-label prescriptions compared to on-label ones (OR 3.4; [1.47; 7.89]; p-value = 0.004). The risks of error and near-miss were reported for 6.3% and 18.2% of total prescriptions, respectively. Of the total of 133 interactions, 47 (35.3%) resulted in ADRs. This study shows the importance of pro-active pharmacovigilance to efficiently highlight ADRs, and the fundamental role of multidisciplinary teams (oncologist, pharmacist, pharmacologist, pediatrician, nurse) in improving patients’ safety during therapy.


  • Open Access

    Biological and Clinical Changes in a Pediatric Series Treated with Off-Label JAK Inhibitors

    by Alessia Pin, Alessandra Tesser, Serena Pastore, Valentina Moressa, Erica Valencic, Anna Arbo, Alessandra Maestro, Alberto Tommasini, Andrea Taddio

    Off-label use of medications is still a common practice in pediatric rheumatology. JAK inhibitors are authorized in adults in the treatment of rheumatoid arthritis, psoriatic arthritis and ulcerative colitis. Although their use is not authorized yet in children, JAK inhibitors, based on their mechanism of action and on clinical experiences in small series, have been suggested to be useful in the treatment of pediatric interferon-mediated inflammation. Accordingly, an increased interferon score may help to identify those patients who might benefit of JAK inhibitors. We describe the clinical experience with JAK inhibitors in seven children affected with severe inflammatory conditions and we discuss the correlation between clinical features and transcriptomic data. Clinical improvements were recorded in all cases. A reduction of interferon signaling was recorded in three out of seven subjects at last follow-up, irrespectively from clinical improvements. Other signal pathways with significant differences between patients and controls included upregulation of DNA repair pathway and downregulation of extracellular collagen homeostasis. Two patients developed drug-related adverse events, which were considered serious in one case. In conclusion, JAK inhibitors may offer a valuable option for children with severe interferon-mediated inflammatory disorders reducing the interferon score as well as influencing other signal pathways that deserve future studies.